New hope for advanced cancer patients? early trial of ABX-001 begins
Disease control
Recruiting now
This early-phase study tests a new drug called ABX-001, given alone or with the immunotherapy pembrolizumab, in people with advanced solid tumors that have stopped responding to standard treatments. The main goals are to check safety and find the best dose. About 27 adults will t…
Phase: PHASE1 • Sponsor: Abalos Therapeutics GmbH • Aim: Disease control
Last updated Jun 02, 2026 11:58 UTC